Yahoo Finance Plus Alphabet announced on Tuesday that co-founders Larry Page and Sergey Brin would relinquish full control of both Google and its parent company to CEO Sundar Pichai.
(Bloomberg) -- Strategists from almost all the top Wall Street banks have come out this week with a nervous message about the U.S. stock market.The latest views hail from Deutsche Bank AG and Goldman Sachs Group Inc., and echo earlier pronouncements from Morgan Stanley, Citigroup Inc. and Bank of America Corp. While investment banks tend to be measured in their outlooks, there are common threads that underpin their predictions that the market is vulnerable. Valuations are at historical extremes,
Early in the coronavirus vaccine race, Novavax (NASDAQ: NVAX) seemed to have secured the third spot behind rivals Moderna (NASDAQ: MRNA) and Pfizer. The U.S. Food and Drug Administration (FDA) authorized the Moderna and Pfizer vaccines in December. Let's take a closer look at what Novavax is doing now that may lead to victory down the road.
It’s no secret that Vanguard, Fidelity and Charles Schwab are three of the most popular and well-known brokerage firms. These financial institutions are also some of the largest, offering a wide range of products and services, from banking and investment … Continue reading → The post Vanguard vs. Fidelity vs. Schwab appeared first on SmartAsset Blog.
THE TRADER A rocky week in the markets has traders, investors, and strategists at Defcon 2, peering into the horizon for the enemy—a stock market correction. But while there are some troubling signals, corrections—drops of 10% from recent highs—don’t just happen, just like bull markets don’t die of old age.
Living in Retirement: Our semi-retired columnist muses on why he's disinclined to begin spending down the savings he worked for three decades to build.
Get ready to make some defensive portfolio moves. At least, that’s the bottom line according to Raymond James strategist Tavis McCourt, who is taking a close look at the issues facing US investors as we put the Labor Day holiday behind us. The key point, according to McCourt, is the sheer number of possible impactors on the market. The COVID virus is still burning its way across the world, and new variants are creeping up. The US Congress still has not come to grips with passing a budget – and m
Don't worry. There's a simple way to play defense.
Following a bearish Friday, it’s been a mixed start to the day. A Bitcoin move back through to $47,000 levels would support a broad-based crypto rally, however.
Is this week's crypto plunge a sign of things to come?
Moderna was a great stock to buy in 2020 and even earlier this year. Here are two biotech stocks that are better buys right now than Moderna. Novavax (NASDAQ: NVAX) could soon be a direct competitor to Moderna.
The broader market is coming off a 4-day losing streak, as investors get more jittery about COVID-19's economic impact.
Economist Laurence Kotlikoff says that savers should focus on smoothing and protecting spending throughout their life, then saving toward retirement. Also: Wait until age 70 to collect Social Security.
When Warren Buffett took over Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in 1965, the company was valued at $19 per share. Berkshire stock's massive size means that its days of explosive growth are probably in the rearview, but investors will likely still be able to bank strong gains by following moves made by the company and its chief executive officer. If you want to replicate The Oracle of Omaha's investing strategy, the single best way to do it is owning Berkshire Hathaway stock.
(Bloomberg) -- Michael Rubin was a freshman at Villanova University when he first displayed a knack for pulling off big deals. Using cash borrowed from a neighbor, he bought $200,000 of overstock sports equipment and soon resold it for a $75,000 profit. He’s been pouncing on opportunities ever since. Today, Rubin has a net worth of about $8 billion, according to the Bloomberg Billionaires Index. Seizing on the disruptive power of internet-based shopping, he has turned sports merchandiser Fanatic
Big pharma stocks appeal to many investors. Why? They often offer relative stability and solid (albeit not always spectacular) growth prospects. Many of these stocks also provide strong dividends. We asked three Motley Fool contributors to pick the smartest big pharma stocks to buy in September.
Fifty-five percent of the adult population in the U.S. is invested in stocks, according to Statista. Adding growth stocks to your portfolio, for instance, could grow your wealth exponentially over time, especially if these stocks are riding megatrends.
Uranium mining stocks are hot Friday. As Financial Times reports today, the price of uranium yellowcake has soared to its highest level seen since 2014 as private investors bid against nuclear power companies for access to the fuel. Sprott in particular, reports Financial Times, has "snapped up" 6 million pounds of physical uranium, worth about $240 million, over the past couple of months, bringing its total holdings to about 24 million pounds.
Shares of lithium mining company Lithium Americas (NYSE: LAC) closed 7.7% higher on Friday. You can thank rival lithium company Albemarle (NYSE: ALB) for that. In its 2021 Investor Day held Friday, Albemarle told investors that a surge in demand for lithium -- which is used to build batteries for electric cars -- is going to lift its profits in 2022.
Despite the ugly price action, most of crypto's true believers are still just that.
AbbVie Inc. (NYSE: ABBV) recently catered, as modest yearly gains almost got wiped out in a single session. Meanwhile, downward pressure continues as the price looks to test the support around US$100 for the third time this year. We will examine the dividend as the stock dips down below the P/E of 30 since a 4.8% yield is certainly interesting at the right price.
Yahoo Finance